ReviewJournal of ophthalmic inflammation and infection2020
A review of ocular adverse events of biological anti-TNF drugs.
Review in Journal of ophthalmic inflammation and infection, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 3 syntheses or guidelines pooled it, 78 citations in OpenAlex.
- Risk of new-onset and recurrent uveitis with different biologics for ankylosing spondylitis: a network meta-analysis.Frontiers in immunology · 2025Pooled it
- Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis-associated uveitis.The Cochrane database of systematic reviews · 2022Pooled it
- Natural and iatrogenic ocular manifestations of rheumatoid arthritis: a systematic review.International ophthalmology · 2022Pooled it
- Current landscape of drug induced retinal vasculitis.Journal of ophthalmic inflammation and infection · 2026Review
- Dual-targeting VEGF and TNF-α with bispecific antibody eyedrops for synergistic treatment of uveitis.Journal of nanobiotechnology · 2026Article
- Concurrent cytomegalovirus iridocyclitis and vitreoretinal lymphoma in the same eye during long-term infliximab therapy: a case report.Journal of ophthalmic inflammation and infection · 2026Article
- Dual-Site Inflammation During Adalimumab Therapy: Birdshot Chorioretinopathy Complicated by Paradoxical Psoriasis.Cureus · 2026Article
- Recurrent acute bilateral cicatricial conjunctivitis as an adverse event of systemic adalimumab for rheumatoid arthritis.Digital journal of ophthalmology : DJO · 2026Article
- Biosimilars in Adult and Pediatric Noninfectious Uveitis.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Rates of Drug-Induced Uveitis: A Review by Medication Class.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Cross-speciality collaborative care in complex immune-mediated inflammatory diseases: treating the person living with the condition.BMC medicine · 2025Review
- Etanercept-induced sarcoidosis presenting with bilateral panuveitis: diagnostic value of ocular signs and therapeutic response to IL-17A inhibition-a case-based review.Clinical rheumatology · 2025Review
- Transient Visual Loss due to Infliximab Administration: A New Adverse Event to Biologic Therapy in Crohn's Disease.ACG case reports journal · 2025Article
- Real-world treatment patterns for patients with non-infectious uveitis in Japan: a descriptive study using a large-scale claims database (J-CAT study).Journal of ophthalmic inflammation and infection · 2025Article
- Treatment of ocular sarcoidosis. Study of 65 patients from a series of 342 from a university hospital in northern Spain.International ophthalmology · 2025Article
- Infliximab-associated bilateral nonarteritic ischemic optic neuropathy in chronic plaque psoriasis treatment.JAAD case reports · 2025Article
- Pharmacogenomic landscape of TNF inhibitors in the Middle Eastern Qatari population.Frontiers in immunology · 2025Article
- Adalimumab-Induced Optic Neuropathy in A Patient with Behçet's Syndrome.European journal of case reports in internal medicine · 2025Article
- Efficacy of biologic and targeted synthetic disease-modifying antirheumatic drugs in non-infectious uveitis in axial spondyloarthropathy and their ocular side effects.Reumatologia · 2025Review
- Ocular Manifestations of IBD: Pathophysiology, Epidemiology, and Iatrogenic Associations of Emerging Treatment Strategies.Biomedicines · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent introduction of biological agents has revolutionized the treatment of chronic immune-inflammatory diseases; however, this new therapy did not come without significant side effects.Through large controlled studies indicating decrease in the number of uveitis flares, the role of TNF inhibitors therapy for non-infectious uveitis gained more ground. Paradoxically to its therapeutic effect, there are reports associating these drugs with the onset or recurrence of inflammatory eye disease.A number of studies have suggested possible roles for anti-TNF-α agents in precipitating or worsening an underlying inflammatory process, including the hypothesis of a disequilibrium in cytokine balance, but to date the mechanisms responsible for these adverse events are not fully understood.A PubMed literature search was performed using the following terms: ophthalmic complication, uveitis, inflammatory eye disease, optic neuritis, neuropathy, adverse events, anti-TNF, TNF alpha inhibitor, infliximab, etanercept, adalimumab, golimumab, certolizumab, and biologics. The data presented in this study was mainly derived from the use of TNF inhibitors in rheumatology, essentially because these drugs have been used for a longer period in this medical field.Many of the ocular adverse events reported on this review may be considered a paradoxical effect of anti-TNF therapy. We found a variety of data associating new onset of uveitis with anti-TNF therapy for rheumatic conditions, predominantly under etanercept.In conclusion, although there is increasing data on ocular adverse events, it remains to be seen whether the suggested link between TNF inhibitors and the onset of ocular inflammation is substantiated by more quality data. Nevertheless, the awareness of potential treatment side effects with anti-TNF should be highlighted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.